Claims

1. Use of uridine monophosphate (UMP) in the manufacture of a composition for treating a non-demented elderly subject suffering from white matter hyperintensities (WMH), Leukoaraiosis or periventricular white matter disease, wherein the elderly subject is a human subject of at least 50 years of age, wherein the composition is to be administered to the elderly subject daily, and wherein the composition comprises:
   (a) 500 – 5000 mg docosahexaenoic acid (DHA),
   (b) 200 – 600 mg choline,
   (c) 400 – 800 mg UMP, and
   (d) 200 – 600 µg folic acid.

2. Use according to claim 1, wherein the composition comprises, per day:
   (a) 900 – 1500 mg docosahexaenoic acid (DHA),
   (b) 200 – 600 mg choline,
   (c) 400 – 800 mg UMP, and
   (d) 200 – 600 µg folic acid.

3. Use according to any one of the preceding claims, for controlling, reducing or suppressing Nogo-A protein levels.

4. Use according to any one of the preceding claims, said composition further comprising vitamin B6, B9 and B12.

5. Use according to any one of the preceding claims, said composition further comprising one or more selected from the group consisting of vitamin C or its equivalents, vitamin E or its equivalents, and selenium.

6. Use according to any one of the preceding claims, said composition further comprising at least one phospholipid.

7. Use according to any one of the preceding claims, said composition being an aqueous composition comprising, per daily dosage or per 100 ml of liquid:
100 – 500 mg EPA,
900 – 1500 mg DHA,
50 – 600 mg phospholipids,
200 – 600 mg choline,
400 – 800 mg UMP (uridine monophosphate),
20 – 60 mg vitamin E (alpha-TE),
60 – 100 mg vitamin C,
40 – 80 µg selenium,
1 – 5 µg vitamin B12,
0.5 – 3 mg vitamin B6, and
200 – 600 µg folic acid.

8. Use according to any one of the preceding claims, wherein said composition is to be enterally administered to the elderly subject at least one time per day for a period of at least 3 weeks.

9. Use of uridine monophosphate (UMP) in the manufacture of a composition for treating an elderly subject suffering from white matter hyperintensities (WMH), Leukoaraiosis or periventricular white matter disease, wherein the elderly subject is a human subject of at least 50 years of age, wherein the composition is to be administered to the subject daily, wherein the composition comprises:
(a) 500 – 5000 mg docosahexaenoic acid (DHA),
(b) 200 – 600 mg choline,
(c) 400 – 800 mg UMP, and
(d) 200 – 600 µg folic acid,
wherein the subject does not suffer from Alzheimer's Disease.

10. Use according to claim 9, wherein the composition is to be administered to the elderly subject daily, wherein the composition comprises:
(a) 900 – 1500 mg docosahexaenoic acid (DHA),
(b) 200 – 600 mg choline,

(c) 400 – 800 mg UMP, and
(d) 200 – 600 µg folic acid.

11. Use according to claim 9 or 10, for controlling, reducing or suppressing Nogo-A protein levels.

12. Use according to any one of claims 9-11, said composition further comprising vitamin B6, B9 and B12.

13. Use according to any one of claims 9-12, said composition further comprising one or more selected from the group consisting of vitamin C or its equivalents, vitamin E or its equivalents, and selenium.

14. Use according to any one of claims 9-13, said composition being an aqueous composition comprising, per daily dosage or per 100 ml of liquid:
100 – 500 mg EPA,
900 – 1500 mg DHA,
50 – 600 mg phospholipids,
200 – 600 mg choline,
400 – 800 mg UMP (uridine monophosphate),
20 – 60 mg vitamin E (alpha-TE),
60 – 100 mg vitamin C,
40 – 80 µg selenium,
1 – 5 µg vitamin B12,
0.5 – 3 mg vitamin B6, and
200 – 600 µg folic acid.

* * * * *